|
Orthologous residues
|
|
TH (human): S19‑p, TH iso2 (human): S19‑p, TH iso3 (human): S19‑p, TH iso5 (human): S19‑p, TH (mouse): S19‑p, TH (rat): S19‑p, TH (cow): S19‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
MN9D ('neuron, mesencephalic')
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
PHOSPHATASE
|
PPP2CA (human)
|
transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
okadaic acid
|
|
|
|
increase
|
|
|
fostreicin
|
|
|
|
increase
|
|
|
|
|
SNCA (human)
|
|
decrease
|
|
|
|
|
SNCA (human)
|
|
decrease
|
SNCA KO induces
|
|
|
|
|
SNCA (human)
|
augment treatment-induced decrease
|
S129A SNCA mutant
|
|
|
|
SNCA (human)
|
|
decrease
|
in dopaminergic tissues
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
phosphorylation
|
|
Comments:
SNCA S129A mutant has higher PPP2CA activation inhibiting TH S19 phosphorylation.
|